This study is limited to spirometric indices, analysis of data on lung volumes and transfer factor being deferred to a later stage. Prediction equations were derived for the FEV1, FVC and FEV1/FVC across the entire age range. For children aged 3–7 years (an age range chosen because the forced expiratory time usually exceeds 1 s in older children), the FEV075 and FEV075/FVC were also derived. Data on FEV0.75, FEV0.75/FVC and forced expired flow when 75% of the FVC has been exhaled (FEF75) were available only for Caucasians. Data (N=36,831) on FEF25–75% were available in 21 datasets. As very few data became available on FEV0.5, this index was not analysed.
>
Procedures
>
Diagnostic Procedure
>
Spirometry
Spirometry
Spirometry is a pulmonary function test that measures the volume and flow of air during inhalation and exhalation.
It provides valuable insights into lung function and can aid in the diagnosis and management of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and lung fibrosis.
Optimizing spirometry research is crucial for enhancing accuracy and reproducibility.
PubCompare.ai is an AI-driven platform that helps researchers locate the best spirometry protocols from literature, preprints, and patents, and compare multiple protocols side-by-side to discover the optimal methods and products for their studies.
By taking spirometry research to the next leve,l this tool can help unlock new discoveries and advance the field of respiratory health.
It provides valuable insights into lung function and can aid in the diagnosis and management of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and lung fibrosis.
Optimizing spirometry research is crucial for enhancing accuracy and reproducibility.
PubCompare.ai is an AI-driven platform that helps researchers locate the best spirometry protocols from literature, preprints, and patents, and compare multiple protocols side-by-side to discover the optimal methods and products for their studies.
By taking spirometry research to the next leve,l this tool can help unlock new discoveries and advance the field of respiratory health.
Most cited protocols related to «Spirometry»
Caucasoid Races
Child
Lung Volumes
Spirometry
Transfer Factor
An application was submitted for a joint ATS and ERS task force to update the 2005 spirometry standards (1 (link)). The task force membership and co-chairs were approved by the ATS and the ERS. Task force members were scientists and physicians with experience in international guidelines and standards; clinical experience in routine lung function testing; and specialist knowledge of spirometry, including research publications. All potential conflicts of interest were disclosed and managed according to the rules and procedures of the ATS and the ERS. A search in the MEDLINE database (using PubMed) for publications containing various terms related to spirometry published from 2004 to 2018 yielded 23,368 citations (search terms listed in Section E3). Task force members reviewed the abstracts and identified 190 as directly relevant to the project and a further 382 as potentially relevant. New publications were monitored after the initial search, and twelve 2018 and 2019 references are included. All manufacturers of spirometry equipment were sent a survey requesting equipment specifications. The task force also reviewed equipment specifications published on the manufacturers’ websites. An international survey of patients was conducted through the European Lung Foundation to elicit their experience in spirometry testing. Using the 2005 standards as the base document, revisions and additions were made on a consensus basis. The recommendations in this document represent a consensus of task force members in regard to the evidence available for various aspects of spirometric measurement (as cited in the document) and otherwise reflects the expert opinion of the task force members for areas in which peer-reviewed evidence was either not available or incomplete. Constraints on the development of these standards are listed in Section E12.
Europeans
Joints
Lung
Patients
Physicians
Spirometry
The Clinical COPD Questionnaire (CCQ) was administered to all subjects. Lung function (FEV1 and FVC) was measured according to the ERS guidelines [1 (link)] using dry wedge spirometry (Masterscope, Jaeger, Breda, The Netherlands) or using a turbine portable spirometer (Micromedical Microlab 3300, Sensormedics BV England). The 36 item Short Form Health Survey (SF-36), a generic health-related quality of life questionnaire [14 (link)], was administered to 49 participants with and without COPD. The St George Respiratory Questionnaire (SGRQ), a disease-specific health-related quality of life questionnaire [4 (link)], was administered to 37 patients with COPD (stage I-III).
Chronic Obstructive Airway Disease
Generic Drugs
Patients
Respiratory Physiology
Respiratory Rate
Spirometry
Ethics Committees
Non-Smokers
Spirometry
African American
Chest
Chronic Obstructive Airway Disease
Disease Progression
Exhaling
Genes
Genetic Diversity
Genome
Genome-Wide Association Study
Hispanics
Inhalation
Spirometry
X-Ray Computed Tomography
Most recents protocols related to «Spirometry»
The respiratory system undergoes various anatomical, physiological and immunological changes with age. Ageing is associated with a progressive decline in respiratory function that accompanies changes in the structure of the chest wall due to loss of supporting tissue, increased air trapping and decreased respiratory muscle strength [28 ]. Respiratory function was measured using the CareFusion Microlab Spirometer with the participant seated. Measurements included forced expiratory volume in one second (FEV1, l), forced vital capacity (FVC, l) and forced expiratory flow (FEF) 25–75%. Measures of lung function (FEV1 and FVC) are associated with all-cause and cardiovascular mortality [29 , 30 ]. Low FEV1 is also recognised as an independent predictor of non-cardiopulmonary comorbidities including diabetes, chronic kidney disease, osteoporosis and dementia [31 –34 ]. For the purposes of this manuscript the highest FEV1 and FVC reading was used. A maximum of five attempts were undertaken to obtain three satisfactory readings. Analyses are only based on participants who obtained at least three satisfactory readings.
Cardiovascular System
Chronic Kidney Diseases
Dementia
Diabetes Mellitus
Exhaling
Muscle Weakness
Osteoporosis
physiology
Respiratory Physiology
Respiratory Rate
Respiratory System
Spirometry
Tissues
Volumes, Forced Expiratory
Wall, Chest
For this prospective, single-center study, patients were recruited between June 1st, 2020 and July 1st, 2020. Data were obtained from medical records of adult patients (18 years of age or older) with laboratory-confirmed COVID-19 hospitalized in the intensive care unit (ICU) of a high complexity hospital from Buenos Aires, Argentina. Data registration included demographic, clinical and laboratory information, severity scores, the radiographic assessment of lung edema (RALE) score,8 (link) and mechanical ventilation measurements. The number of patients who died or been discharged, and those that stayed in ICU until August 31st, 2020 was recorded. Additionally, ICU length of stay was determined.
TTE was performed within the three days after ICU admission. Non-inclusion criteria were therapeutic effort adaptation, extracorporeal circulation membrane or inhaled nitric oxide requirement, obesity (body mass index > 30 kg/m2), history of chronic lung disease defined by spirometry as forced expiratory volume in the first second/forced vital capacity <0.75 or pulmonary hypertension defined as pulmonary systolic blood pressure >35 mmHg by any method of assessment, patent foramen ovale (PFO) or any defect in the cardiac interatrial or interventricular septum, history of Rendu Osler Weber Syndrome, and hepatic cirrhosis. Due to the fact that we routinely use TTE to assess the circulatory status of mechanically ventilated patients with COVID-19 in our ICU, TTE was considered a component of standard care. Nevertheless, contrast TTE is not routinely performed, therefore written patient's consent was solicited. Also written and oral information about the study was given to the families. The study was approved by the institutional ethics committee of our hospital under protocol number 5657. Our manuscript complies with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement guidelines for observational cohort studies9 (link) (Table E1 of Supplementary material ).
TTE was performed within the three days after ICU admission. Non-inclusion criteria were therapeutic effort adaptation, extracorporeal circulation membrane or inhaled nitric oxide requirement, obesity (body mass index > 30 kg/m2), history of chronic lung disease defined by spirometry as forced expiratory volume in the first second/forced vital capacity <0.75 or pulmonary hypertension defined as pulmonary systolic blood pressure >35 mmHg by any method of assessment, patent foramen ovale (PFO) or any defect in the cardiac interatrial or interventricular septum, history of Rendu Osler Weber Syndrome, and hepatic cirrhosis. Due to the fact that we routinely use TTE to assess the circulatory status of mechanically ventilated patients with COVID-19 in our ICU, TTE was considered a component of standard care. Nevertheless, contrast TTE is not routinely performed, therefore written patient's consent was solicited. Also written and oral information about the study was given to the families. The study was approved by the institutional ethics committee of our hospital under protocol number 5657. Our manuscript complies with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement guidelines for observational cohort studies9 (link) (
Acclimatization
Adult
Cardiovascular System
COVID 19
Extracorporeal Circulation
Foramen Ovale, Patent
Heart
Hereditary Hemorrhagic Telangiectasia
Index, Body Mass
Institutional Ethics Committees
Liver Cirrhosis
Lung
Lung Diseases
Mechanical Ventilation
Obesity
Oxide, Nitric
Patients
Pulmonary Edema
Pulmonary Hypertension
Radiography
Spirometry
Systolic Pressure
Therapeutics
Tissue, Membrane
Ventricular Septum
Vital Capacity
Volumes, Forced Expiratory
This observational, real-life study was conducted at the Bordeaux University Hospital, France. The study was conducted in accordance with the Declaration of Helsinki principles and approved by the South-West and Overseas Protection Committee (CPP) III. According to the law in force in France, the non-opposition of the patient and/or his legal representatives for patients under 18 years of age was obtained for the use of clinical data and lung function testing results which did not require the patients' informed consent.
The study included patients with confirmed CF (sweat chloride >60 mmol/L and/or CFTR gene mutations) followed at the paediatric or adult CF centres older than 5 years old, able to perform forced spirometry and using home spirometry in routine care between July 2015 and June 2021. Patients were included at the first use of the Spirobank smart® and were followed up for 6 months. At the beginning of the follow-up with the Spirobank smart®, patients were advised to perform at least 3 measurements per week for children (6–12 years) and teenagers (12–18 years), and at least one weekly measurement for adults. The advised number of measurements was chosen to fit with the number of respiratory physiotherapy sessions per week performed by patients (i.e., at least 3 times a week for children and at least once for adults). Children were also advised to be helped by their parents to performed home spirometry. The physiotherapists were encouraged to remind and/or to help patients to use the device during respiratory physiotherapy sessions.
The study included patients with confirmed CF (sweat chloride >60 mmol/L and/or CFTR gene mutations) followed at the paediatric or adult CF centres older than 5 years old, able to perform forced spirometry and using home spirometry in routine care between July 2015 and June 2021. Patients were included at the first use of the Spirobank smart® and were followed up for 6 months. At the beginning of the follow-up with the Spirobank smart®, patients were advised to perform at least 3 measurements per week for children (6–12 years) and teenagers (12–18 years), and at least one weekly measurement for adults. The advised number of measurements was chosen to fit with the number of respiratory physiotherapy sessions per week performed by patients (i.e., at least 3 times a week for children and at least once for adults). Children were also advised to be helped by their parents to performed home spirometry. The physiotherapists were encouraged to remind and/or to help patients to use the device during respiratory physiotherapy sessions.
Adolescent
Adult
CFTR protein, human
Child
Chlorides
Medical Devices
Mutation
Parent
Patient Representatives
Patients
Physical Therapist
Respiratory Rate
Spirometry
Sweat
Therapy, Physical
At inclusion, we collected clinical data from the patient's medical files including the age, gender, body mass index (BMI), CFTR mutations, comorbidities [pancreatic insufficiency, cystic fibrosis related diabetes (CFRD)], chronic colonization status for pseudomonas aeruginosa (PA) and methicillin susceptible staphylococcus aureus (MSSA), treatments (inhaled bronchodilator, inhaled corticosteroid, CFTR modulators) and results of the last lung function testing (LFT) performed in a dedicated laboratory at the physiology department of the University Hospital of Bordeaux (i.e., FEV1, FVC, FEF25-75, and FEV1/FVC).
During the follow-up period, we also collected LFT results from both the first lung function testing performed in our lab after inclusion (named thereafter FEV1conv, FVCconv, and FEF25-75conv, FEV1/FVCconv) and results from forced spirometry measurements performed at home with Spirobank smart®. Of note, results from forced spirometry performed with the Spirobank smart® are automatically recorded in the dedicated smartphone application by Bluethooth® at each use. Data recorded by the application (Pneumotel®) are then anonymously transmitted by the patient in real time to the Pneumotel® platform Data are then collected by AquiRespi, another platform dedicated to the coordination of respiratory care in the New Aquitaine region (France) which is in contact with the patients' practitioners. For each patient, all data from home spirometry collected by AquiRespi during the 6 months after inclusion were collected by the investigators (FB, GB). We specifically identified the results of the home spirometry closest to the conventional LFT as FEV1home M1, FVChome M1, and FEF25-75home M1, FEV1/FVChome M1, and those of the second closest home spirometry to conventional LFT as FEV1home M2, FVChome M2, and FEF25-75home M2, FEV1/FVChome M2. Patient participation in the study was discontinued if the last recorded measure occurred before the end of the observation period (hereafter called early stoppers).
During the follow-up period, we also collected LFT results from both the first lung function testing performed in our lab after inclusion (named thereafter FEV1conv, FVCconv, and FEF25-75conv, FEV1/FVCconv) and results from forced spirometry measurements performed at home with Spirobank smart®. Of note, results from forced spirometry performed with the Spirobank smart® are automatically recorded in the dedicated smartphone application by Bluethooth® at each use. Data recorded by the application (Pneumotel®) are then anonymously transmitted by the patient in real time to the Pneumotel® platform Data are then collected by AquiRespi, another platform dedicated to the coordination of respiratory care in the New Aquitaine region (France) which is in contact with the patients' practitioners. For each patient, all data from home spirometry collected by AquiRespi during the 6 months after inclusion were collected by the investigators (FB, GB). We specifically identified the results of the home spirometry closest to the conventional LFT as FEV1home M1, FVChome M1, and FEF25-75home M1, FEV1/FVChome M1, and those of the second closest home spirometry to conventional LFT as FEV1home M2, FVChome M2, and FEF25-75home M2, FEV1/FVChome M2. Patient participation in the study was discontinued if the last recorded measure occurred before the end of the observation period (hereafter called early stoppers).
Adrenal Cortex Hormones
Bronchodilator Agents
CFTR protein, human
Cystic Fibrosis
Diabetes Mellitus
Gender
Index, Body Mass
Methicillin
Mutation
Pancreatic Insufficiency, Exocrine
Patient Participation
Patients
physiology
Pseudomonas aeruginosa
Respiratory Rate
Spirometry
Staphylococcus aureus
The analyses were performed using Graphpad Prism 5.1 software (GraphPad Software, La Jolla, CA). Results are presented as absolute values with percentage [n/N (%)] for categorial variables and as means ± standard deviation (mean ± SD) or median and interquartile ranges (median [IQR25; IQR75] for quantitative variables.
Adherence was determined by the number of Spirobank smart® uses. Since the recommendations were different for children/teenagers and adults, adherence was assessed by the number of uses normalized by the recommended minimum objective (i.e.,; 3 per week for children/teenagers and 1 per week for adults corresponding to 78 and 26 tests for children/teenagers and adults, respectively during the whole follow-up period) and thus expressed as a percentage. Adherence was also analysed using a threshold to identify excellent users (use >80% of the objective rate), good users (use between 50% and 80%), moderate users (use between 30% and 50%) and low users (use < 30%).
Reliability was assessed using Pearson or Spearman correlation tests (Pearson or Spearman tests), Bland and Altman test and intraclass correlation coefficients. Intra-methods agreement was assessed between the two closest measured of conventional LFT. Inter-methods agreement and agreement over time were assessed between conventional LFT and the closest or the second closest home spirometry to the conventional LFT respectively.
We also assessed home spirometry test-to-test variability over time by determining (i) the maximal variability, expressed as absolute value (Δmax; e.g., ΔmaxFEV1 = MaxFEV1 - MinFEV1) or normalized by the mean of the parameter, (ii) the test-to-test average variability expressed as absolute [Δaverage; e.g., ΔaverageFEV1= (FEV1n + 1- FEV1n)/n, were n is the number of the tests] or normalized by the mean of the parameter and (iii) the coefficient of variation (CoV; e.g., CoVFEV1 = SDFEV1/MeanFEV1).
Adherence, reliability and variability over time were assessed in the whole population and compared between children, teenagers and adults. Comparisons between groups were performed using Kaplan-Meyer curves and Log-rank test, Fisher's exact test or Chi square test for categorial variables and using were performed using Mann-Whitney or Kruskal-Wallis tests with Dunn post-test for quantitative variables. A p value < 0.05 was considered significant.
Adherence was determined by the number of Spirobank smart® uses. Since the recommendations were different for children/teenagers and adults, adherence was assessed by the number of uses normalized by the recommended minimum objective (i.e.,; 3 per week for children/teenagers and 1 per week for adults corresponding to 78 and 26 tests for children/teenagers and adults, respectively during the whole follow-up period) and thus expressed as a percentage. Adherence was also analysed using a threshold to identify excellent users (use >80% of the objective rate), good users (use between 50% and 80%), moderate users (use between 30% and 50%) and low users (use < 30%).
Reliability was assessed using Pearson or Spearman correlation tests (Pearson or Spearman tests), Bland and Altman test and intraclass correlation coefficients. Intra-methods agreement was assessed between the two closest measured of conventional LFT. Inter-methods agreement and agreement over time were assessed between conventional LFT and the closest or the second closest home spirometry to the conventional LFT respectively.
We also assessed home spirometry test-to-test variability over time by determining (i) the maximal variability, expressed as absolute value (Δmax; e.g., ΔmaxFEV1 = MaxFEV1 - MinFEV1) or normalized by the mean of the parameter, (ii) the test-to-test average variability expressed as absolute [Δaverage; e.g., ΔaverageFEV1= (FEV1n + 1- FEV1n)/n, were n is the number of the tests] or normalized by the mean of the parameter and (iii) the coefficient of variation (CoV; e.g., CoVFEV1 = SDFEV1/MeanFEV1).
Adherence, reliability and variability over time were assessed in the whole population and compared between children, teenagers and adults. Comparisons between groups were performed using Kaplan-Meyer curves and Log-rank test, Fisher's exact test or Chi square test for categorial variables and using were performed using Mann-Whitney or Kruskal-Wallis tests with Dunn post-test for quantitative variables. A p value < 0.05 was considered significant.
Adolescent
Adult
Child
prisma
Spirometry
Top products related to «Spirometry»
Sourced in United States
The Vmax 22 is a laboratory equipment product manufactured by Cardinal Health. It is designed to perform various analytical tasks within a research or clinical laboratory setting. The core function of the Vmax 22 is to provide accurate and reliable measurements and analysis of samples. The specific capabilities and features of the Vmax 22 are not available in this factual and unbiased description.
Sourced in United Kingdom, Ireland
Ventolin is a handheld, portable medical device designed to administer medication for the treatment of respiratory conditions. It functions as an inhalation device to deliver bronchodilator medication directly to the lungs, providing relief for symptoms such as shortness of breath and wheezing.
Sourced in United States
The Model 2130 is a compact and versatile lab equipment piece designed to perform fundamental laboratory tasks. It features a user-friendly interface and robust construction to support common laboratory operations.
Sourced in Sweden
The NIOX MINO is a compact, portable device designed for the measurement of nitric oxide (NO) in exhaled breath. It provides a simple and accurate method for assessing airway inflammation, which can be a useful indicator of respiratory conditions such as asthma.
Sourced in Italy
The Pony FX is a compact, high-performance laboratory centrifuge designed for a variety of applications. It features a brushless motor and can achieve speeds of up to 6,000 RPM, making it suitable for a range of sample separation tasks. The Pony FX is a versatile and reliable piece of equipment for use in clinical, research, and educational settings.
Sourced in United States
The VMAX2130 is a laboratory equipment product manufactured by Cardinal Health. It is a multi-functional device designed for use in various laboratory settings. The core function of the VMAX2130 is to perform a range of analytical and measurement tasks, though the specific details of its intended use are not provided in this factual, unbiased description.
Sourced in Italy
The Quark PFT is a pulmonary function testing device manufactured by Cosmed. It is designed to measure various respiratory parameters, such as lung volumes, flow rates, and gas exchange. The Quark PFT provides comprehensive data on an individual's respiratory function.
Sourced in Germany, United States
The MasterScreen Body is a lung function testing system designed for clinical use. It measures various parameters related to pulmonary function, including lung volumes and airflow rates.
Sourced in United States
The Vmax 229 is a laboratory instrument designed for quantitative spectroscopic analysis. It provides precise measurements of absorbance, transmittance, and fluorescence in various sample types. The core function of the Vmax 229 is to perform accurate and reliable spectroscopic analyses in a variety of research and testing applications.
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
More about "Spirometry"
Spirometry is a crucial pulmonary function test that measures the volume and flow of air during inhalation and exhalation.
It provides invaluable insights into lung function and plays a pivotal role in the diagnosis and management of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and lung fibrosis.
Optimizing spirometry research is essential for enhancing the accuracy and reproducibility of these measurements.
PubCompare.ai is an innovative AI-driven platform that helps researchers locate the best spirometry protocols from literature, preprints, and patents.
By comparing multiple protocols side-by-side, this tool allows researchers to discover the optimal methods and products for their studies, taking spirometry research to the next level.
This can unlock new discoveries and advance the field of respiratory health.
The Vmax 22, Ventolin, Model 2130, NIOX MINO, Pony FX, VMAX2130, Quark PFT, and MasterScreen Body are some of the key spirometry devices and products used in research and clinical settings.
These tools, combined with advanced data analysis techniques like SAS version 9.4, can enhance the precision and reliability of spirometry measurements, leading to more accurate diagnoses and better patient outcomes.
By utilizing the insights gained from PubCompare.ai and leveraging the latest spirometry technologies, researchers can take their studies to new heights, driving forward the understanding and management of respiratory diseases.
This holistic approach to spirometry research can truly make a difference in the lives of patients and advance the field of respiratory health.
It provides invaluable insights into lung function and plays a pivotal role in the diagnosis and management of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and lung fibrosis.
Optimizing spirometry research is essential for enhancing the accuracy and reproducibility of these measurements.
PubCompare.ai is an innovative AI-driven platform that helps researchers locate the best spirometry protocols from literature, preprints, and patents.
By comparing multiple protocols side-by-side, this tool allows researchers to discover the optimal methods and products for their studies, taking spirometry research to the next level.
This can unlock new discoveries and advance the field of respiratory health.
The Vmax 22, Ventolin, Model 2130, NIOX MINO, Pony FX, VMAX2130, Quark PFT, and MasterScreen Body are some of the key spirometry devices and products used in research and clinical settings.
These tools, combined with advanced data analysis techniques like SAS version 9.4, can enhance the precision and reliability of spirometry measurements, leading to more accurate diagnoses and better patient outcomes.
By utilizing the insights gained from PubCompare.ai and leveraging the latest spirometry technologies, researchers can take their studies to new heights, driving forward the understanding and management of respiratory diseases.
This holistic approach to spirometry research can truly make a difference in the lives of patients and advance the field of respiratory health.